-- Preclinical data suggest cancers vary in sensitivity to mechanisms of CD27 immune modulation -- -- Clinical experience with varlilumab is consistent with immune co-stimulation and regulatory T cell depletion mechanisms, a potential unique benefit for varlilumab -- -- Multiple Phase 1/2 varlilumab combination studies currently ongoing -- HAMPTON, N.J., Nov. 6, 2015 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today presented new preclinical data on varlilumab, a fully human monoclonal agonist antibody that binds and activates CD27, a critical co-stimulatory molecule in the immune activation cascade. Results suggest that cancers may respond to CD27 immune modulation by...
↧